Compare Crispr Therapeutics AG (CRSP) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fox Corp Class B — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Fox Corp Class B trades at $49.5 (market cap $21.85B). The key difference: Fox Corp Class B is far larger — about 4.4× Crispr Therapeutics AG's market cap, and Fox Corp Class B pays a 1.13% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | FOX | |
|---|---|---|
Market Cap | $4.97B | $21.85B |
Sector | Health | Media |
52-Week High | $76.78 | $67.76 |
52-Week Low | $44.34 | $44.39 |
Enterprise Value | $3.32B | $25.83B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
FOX trades at $50.22, up 3.02% with bullish technical signals and strong earnings beats. Recent Q1 2026 EPS of $1.32 exceeded expectations by 33.6%, continuing a pattern of outperformance. The company shows improved cash flow with 2025 operating cash flow reaching $3.32 billion, while revenue grew to $16.30 billion. Technical indicators show mixed signals with RSI at neutral levels but ADX suggesting strong trend momentum.
The outlook remains positive with analyst price targets suggesting 27-39% upside potential. Key risks include competitive pressures in streaming and potential volatility from the recent Roku acquisition. Wall Street sentiment is cautiously optimistic with 43% buy ratings, though the stock faces near-term execution challenges with projected 2026 cash flow turning negative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
